Ontology highlight
ABSTRACT:
SUBMITTER: Bringhen S
PROVIDER: S-EPMC8248157 | biostudies-literature | 2021 Jun
REPOSITORIES: biostudies-literature
Bringhen Sara S Voorhees Peter M PM Plesner Torben T Mellqvist Ulf-Henrik UH Reeves Brandi B Sonneveld Pieter P Byrne Catriona C Nordström Eva E Harmenberg Johan J Obermüller Jakob J Richardson Paul G PG
British journal of haematology 20210106 6
An updated survival analysis was conducted for the Phase II study O-12-M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (including bortezomib and lenalidomide). Partial response or better was seen in 31%. After a 46-month median overall survival (OS) follow-up, melflufen plus dexamethasone had a median OS of 20·7 months (75th percentile OS, 47·5 months). The median time-to-next treatmen ...[more]